Scilex Holding Company has announced a Memorandum of Understanding for a collaboration agreement with ACEA, a China-based company focused on innovative treatments for high unmet needs. Under this MOU, ACEA may gain exclusive rights to develop and commercialize ZTlido® in mainland China, Taiwan, Hong Kong, and Macau, encompassing both the current formulation and a potential next-generation 3X version, SP-103. This agreement also grants Scilex the opportunity to further expand collaboration with ACEA across its portfolio of non-opioid pain management products in the Greater China region.

ZTlido® is a lidocaine topical system approved for relieving neuropathic pain associated with post-herpetic neuralgia (PHN). It addresses current limitations of lidocaine patches with improved adhesion and continuous pain relief over a 12-hour period. The pain management market is projected to reach US$101.27 billion by 2029, growing at a CAGR of 4.3% from 2022 to 2030. In mainland China alone, the market size was US$17.5 billion in 2022, with an annual growth rate of 5.64%.

ACEA, expressed enthusiasm about the commercial potential of ZTlido® and other Scilex products in Greater China, emphasizing their commitment to expanding patient access to innovative pain management solutions. Jaisim Shah, CEO and President of Scilex, underscored the agreement's alignment with their mission to provide effective non-opioid medicines for acute and chronic pain patients globally, highlighting the importance of broadening access to these advancements in pain management.

 

Source: globenewswire.com

Report Abuse